PARP1 and glioma: This is consistent with previous work by Gupta and colleagues, who demonstrated that siRNA‐mediated knockdown of either N‐methylpurine DNA glycosylase (MPG) or XRCC1 (two indispensable components of a functional BER pathway) did not confer temozolomide sensitivity in resistant glioma cell lines [152], even though PARP1 can act as a scaffold to promote BER‐mediated repair of alkylation damage [153].